U.S. stocks plunged nearly 2 percent or more, with the Dow wiping out gains for the year on escalating tensions between Greece and its creditors.» Read More
Speculation is swirling that Elan could be on the brink of merger after the firm hired Citigroup to conduct a strategic review. Find out what the Fast Money traders are hearing.
Stocks ended mixed Tuesday as tech and oil stocks were buoyed by bargain hunting, but the undercurrent of earnings worry took down the Dow.
During his lunchtime keynote speech here at the JPMorgan Healthcare Conference JPM Chairman and CEO Jamie Dimon was asked to give his worst-case scenario for the economy. He said that'd be a 1982-type recession lasting about two years and with unemployment "North of 10 percent." Dimon said it would be "Irrational to not be prepared for that."
Stocks wobbled Tuesday, paring some gains, though the tech-heavy Nasdaq remained higher.
Not surprisingly it was standing room only in the grand ballroom of the Westin St. Francis Hotel in San Francisco for the Roche presentation this morning at the JPMorgan Healthcare Conference.
Wall Street was looking at a slightly lower open Monday as traders took a leery view of the kickoff to earnings season.
Will M&A activity boost biotech stocks in 2009?
Stocks snapped a three-day winning streak Monday as traders cashed in some of their chips from last week's rally following some dismal reports on the telecom and financial sectors.
Stocks turned mixed Monday, the second day of trading in the new year, as a construction report came in much better than expected, as did U.S. auto sales. Stocks started off the day sharply lower as investors cashed in some of their chips after last week's rally that pushed the Dow up more than 6 percent and past the key 9,000 mark.
Biotechnology stocks are getting a lot of chatter already in this very young year.
The "Financial Times" apparently got a one-on-one interview with Pfizer Chairman and CEO Jeff Kindler and is playing up what he said with the headline, "Pfizer eyes merger deal with large rival."
Stocks declined Monday, the second day of trading in the new year, after a rally last week that pushed the Dow up more than 6 percent and past the key 9,000 mark. A report that showed construction spending fell by half of what was expected helped shave some of the loss.
We begin the "real" New Year with stocks at a 6-week high, and the S&P 500 24 percent above its November 20 low. Now let's see if we can change leadership: health care and consumer stocks have generally outperformed in the past few weeks, though recently industrial stocks have improved. A shift toward less defensive names would be a welcome development.
Wall Street looked set to open lower in the second day of trading of the year after Friday's rebound, with investors expected to take some profits following the Dow's rise to more than 9,000.
Everyone loves a winner. Following are the best performing stocks for 2008 for the Dow, Nasdaq and the S&P. But will they perform as well this year?
Now that 2008 is just about over, here's a look at the top yielding stocks in the Dow that would make up your portfolio if you followed the popular Dogs of the Dow investment strategy.
Merck, Lilly and Pfizer are all trading substantially higher. Will this bear market remedy keep working in the new year?
If you’re looking to put a little bite into your portfolio should you consider the "Dogs Of The Dow?"
Cramer makes the call on viewers' favorite stocks in a special, extended Lightning Round, including PepsiCo, Verizon, Baidu, Boeing and others.
As we head into the holiday break and the bloggable newsflow slows to a trickle, I am digging into the overflowing mailbag while filling in for my vacationing colleague Scott Wapner at the Nasdaq this week.